Therefore, we collected approved drugs that act as inhibitors for these pathways (such as Valproic acid as HDAC inhibitor, Tranilast as TGF-β inhibitor, Fasudil as Rho kinase inhibitor, and Tideglusib as GSK3β inhibitor in Supplementary Fig. S2A,B) to induce neuronal reprogramming on GBM cells. This evidence concerns the gene TGFB1 and glioblastoma.